Post-transplant lymphoproliferative disorders |
| |
| Authors: | Emina Emilia Torlakovic Denis Bailey |
| |
| Institution: | 1. CEA Saclay, DSM/IRFU, 91191 Gif-sur-Yvette Cedex, France;2. University of Lyon, Université Claude Bernard Lyon 1, CNRS-IN2P3, Institut de Physique Nucléaire de Lyon, F-69622, Villeurbanne, France;3. Institut Néel, CNRS/UJF, 25 rue des Martyrs, BP 166, 38042 Grenoble, France;4. CSNSM, University of Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, 91405 Orsay, France;5. Karlsruher Institut für Technologie, Institut für Experimentelle Kernphysik, Gaedestr. 1, 76128 Karlsruhe, Germany;6. Karlsruher Institut für Technologie, Institut für Kernphysik, Postfach 3640, 76021 Karlsruhe, Germany;7. Laboratoire de Photonique et de Nanostructures, CNRS, Route de Nozay, 91460 Marcoussis, France;8. Karlsruher Institut für Technologie, Institut für Prozessdatenverarbeitung und Elektronik, Postfach 3640, 76021 Karlsruhe, Germany;9. University of Oxford, Department of Physics, Keble Road, Oxford OX1 3RH, UK;10. University of Sheffield, Department of Physics and Astronomy, Sheffield, S3 7RH, UK;11. CEA Saclay, DSM/IRAMIS, 91191 Gif-sur-Yvette Cedex, France;12. JINR, Laboratory of Nuclear Problems, Joliot-Curie 6, 141980 Dubna, Moscow Region, Russian Federation;1. Department of Pathology, Stanford University, Stanford, CA 94305;2. Department of Pathology, Oregon Health & Science University, Portland, OR 97239 |
| |
| Abstract: | Post-transplant lymphoproliferative disorders (PTLD) are the second most frequent neoplasia in transplant patients after skin carcinomas. They occur following both solid organ transplants (SOT) and haematopoietic stem cell transplants (HSCT). Most PTLD in solid organ recipients are of host origin, whereas in HSCT recipients they are most often of donor origin. The EBV status of the recipient and the donor, the type of transplant, the type of immunosuppressive therapy used, and the time after transplant are all important parameters that have been associated with the incidence and the type of PTLD. Although most PTLD are B-cell lesions up to 15% may be T-cell or NK-cell type. Most PTLD are associated with EBV, but EBV-negative PTLD are also clearly recognized. In the 2008 WHO classification of lymphoid neoplasms (ref) PTLD are subclassified according to their histological and immunophenotypic characteristics into early lesions, polymorphic type, monomorphic type, and classical Hodgkin lymphoma-type. Overall PTLD mortality rates are around 50%, but new therapies that include early treatment with rituximab and novel anti-EBV therapies promise better outcomes. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
